Last mentioned: Mar 19, 2026
Biofrontera and DarioHealth reported Q4 2025 results on March 19, 2026, highlighting a strategic shift from aggressive growth to sustainable profitability. While Biofrontera focuses on expanding its dermatology market share with Ameluz, DarioHealth is leveraging its B2B2C model to drive high-margin digital health revenue.
Armanino Foods and Biofrontera Inc. both reported record-breaking fourth-quarter and full-year 2025 financial results on March 19, 2026. These reports highlight strong execution in the specialty food and dermatological pharmaceutical sectors, respectively.
This page surfaces every story mentioning Biofrontera Inc. across our finance coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running finance beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Biofrontera Inc. was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |